Psychopharmacogenetics - a Challenge for Pharmacotherapy in Psychiatry
Authors:
- 1 January 2001
- journal article
- review article
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 2 (4) , 178-183
Abstract
Differences in response to treatment or the incidence of adverse drug effects are quite common in clinical psychopharmacotherapy. Although several factors may account for these discrepancies, there is increasing knowledge that genetic factors play a major role. The aim of pharmacogenetics, a new and rapidly growing field in research, is to elucidate the variability in drug response and metabolism due to hereditary differences. According to the hypotheses on the mechanisms of drug action, several mutations in genes coding for neurotransmitter receptors, degrading enzymes, transport proteins or enzymes of the drug metabolizing system (P-450 isoenzymes) have been identified and investigated in psychiatric disorders over the last years. Although some controversy exists among the results, many studies are supportive of the hypothesis that psychopharmacogenetics will be helpful in predicting an individual patient's drug response while minimising the rate of side effects.Keywords
This publication has 38 references indexed in Scilit:
- Association of Short-Term Response to Haloperidol Treatment With a Polymorphism in the Dopamine D2 Receptor GeneAmerican Journal of Psychiatry, 2001
- Applications of pharmacogenetics in psychiatry: personalisation of treatmentExpert Opinion on Pharmacotherapy, 2001
- Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life DepressionNeuropsychopharmacology, 2000
- The Challenges of PsychopharmacogeneticsThe American Journal of Human Genetics, 1999
- Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigreesJournal of Psychiatric Research, 1998
- G proteins and hypertension: An alternative candidate gene approachKidney International, 1998
- Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the ratBrain Research, 1996
- Dopamine D3 receptor Gly9/Ser9 polymorphism and schizophrenia: no increased frequency of homozygosity in German familial casesSchizophrenia Research, 1996
- Association between clozapine response and allelic variation in the 5-HT2C receptor geneNeuroReport, 1995
- An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.Journal of Clinical Investigation, 1990